Literature DB >> 10843657

Cutting edge: T cell-mediated pathology in murine Lyme borreliosis.

M D McKisic1, W L Redmond, S W Barthold.   

Abstract

Even in the absence of an appropriate model or direct evidence, T cells have been hypothesized to exacerbate the manifestations of Lyme disease. To define definitely the role of T cells in Lyme disease, the course of disease in immunocompetent and B cell-deficient mice was compared. By 8 wk postinoculation, immunocompetent mice resolved both carditis and arthritis, whereas foci of myocarditis and severe destructive arthritis characterized disease of B cell-deficient mice. Cell transfer experiments using infected B6-Rag1 knock out mice demonstrated that: 1) innate immunity mediated the initial sequelae of infection, 2) transferring both naive T cells and B cells induced resolution of carditis and arthritis, 3) infected mice reconstituted with T cells developed myocarditis and severe destructive arthritis, and 4) CD4+ T cells were responsible for the observed immune-mediated pathology. These data demonstrate directly the deleterious effect of T cells in Lyme disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843657     DOI: 10.4049/jimmunol.164.12.6096

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism.

Authors:  Marije Oosting; Frank L van de Veerdonk; Thirumala-Devi Kanneganti; Patrick Sturm; Ineke Verschueren; Anneleen Berende; Jos W M van der Meer; Bart-Jan Kullberg; Mihai G Netea; Leo A B Joosten
Journal:  Eur J Immunol       Date:  2010-12-09       Impact factor: 5.532

2.  Relative contributions of innate and acquired host responses to bacterial control and arthritis development in Lyme disease.

Authors:  Xiaohui Wang; Ying Ma; John H Weis; James F Zachary; Carsten J Kirschning; Janis J Weis
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae.

Authors:  Harald Gelderblom; Jens Schmidt; Diana Londoño; Yunhong Bai; Jacqueline Quandt; Ron Hornung; Adriana Marques; Roland Martin; Diego Cadavid
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  BB0238, a presumed tetratricopeptide repeat-containing protein, is required during Borrelia burgdorferi mammalian infection.

Authors:  Ashley M Groshong; Danielle E Fortune; Brendan P Moore; Horace J Spencer; Robert A Skinner; William T Bellamy; Jon S Blevins
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

5.  CD4+ T cells promote antibody production but not sustained affinity maturation during Borrelia burgdorferi infection.

Authors:  Rebecca A Elsner; Christine J Hastey; Nicole Baumgarth
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

6.  Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Joseph Kuo; Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

Review 7.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 8.  IgM in microbial infections: taken for granted?

Authors:  Rachael Racine; Gary M Winslow
Journal:  Immunol Lett       Date:  2009-06-17       Impact factor: 3.685

9.  Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Authors:  Nicholas J Kotloski; Dean T Nardelli; Sara Heil Peterson; Jose R Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

Review 10.  Microbiota-mediated mucosal inflammation in arthritis.

Authors:  Meagan E Chriswell; Kristine A Kuhn
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-03-06       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.